Herpes immunization - on the threshold

Journal of the European Academy of Dermatology and Venereology

Volumn 7, Issue 2, 1996, Pages 120-128

  Stanberry, L R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Genital herpes; Herpes simplex virus; Immunotherapy; Vaccine

Indexed keywords

HERPES SIMPLEX VACCINE;

HERPES SIMPLEX VIRUS; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION;

EID: 0029742866     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/0926-9959(96)00071-2     Document Type: Review

References (42)

1. Kinghorn GR. Genital herpes: natural history and treatment of acute episodes. J Med Virol Suppl 1993;1:33-38.
2. Stanberry LR. Genital and neonatal herpes simplex virus infections: epidemiology, pathogenesis and prospects for control. Rev Med Virol 1993;3:37-46.
3. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990;69:19-36.
4. Reeves WC, Corey L, Adams HG et al. Risk of recurrence after first episode after first episode genital herpes: relation to HSV type and antibody response. New Engl J Med 1981;305:315-319.
5. Stanberry LR. Pathogenesis of herpes simplex virus infection and animal models for its study. Curr Top Microbiol Immunol 1992;179:15-30.
6. Stanberry LR, Floyd-Reising SA, Connelly BL et al. Herpes simplex viremia: a report of eight pediatric cases and review of the literature. Clin Infect Dis 1994;18:401-407.
7. Klein RJ. Initiation and maintenance of latent herpes simplex virus infections: the paradox of perpetual immobility and continuous movement. Rev Infect Dis 1985:7:21-30.
8. Committee on Issues and Priorities for New Vaccine Development. Appendix I: prospects for immunizing against herpes simplex viruses 1 and 2. In: New Vaccine Development: Establishing Priorities. National Academy Press, Washington, DC, 1985:280-312.
9. Frank SB. Formolized herpes virus therapy and the neutralizing substance in herpes simplex. J Invest Dermatol 1938;1:267-282.
10. Kern AB, Schiff BL. Vaccine therapy in recurrent herpes simplex. Arch Dermatol 1964;89:844-845.
11. Cappel R. Comparison of the humoral and cellular immune responses after immunization with live. UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Arch Virol 1976;52:29-35.
12. Kitces EN, Morahan PS, Tew JG et al. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine. Infect Immun 1977;16:955-960.
13. Stanberry LR, Bernstein DI, Burke RL et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155:914-920.
14. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-614.
15. Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994;68:689-696.
16. Farrell HE, McLean CS, Harley C et al. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 1994;68:927-932.
17. + T lymphocytes. J Immunol 1995;155:259-265.
18. Cappel R, Sprecher S, Rickaert F et al. Immune response to a DNA free herpes simplex vaccine in man. Arch Virol 1982;73:61-67.
19. + )MRC: toward prevention of herpes simplex virus infections in human subjects. Med Microbiol Immunol 1980;169:39-51.
20. -)MRC towards prevention of herpes genitalis. Br J Vener Dis 1982;58:381-386.
21. Skinner GRB, Fink CG, Cowan M et al. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med Microbiol Immunol 1987;176:161-167.
22. Mertz GJ, Ashley R, Burke RL et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990;161:653-660.
23. Ashley R, Mertz G, Clark H et al. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 1985;56:475-481.
24. Kutinova L, Slichtova VA, Vonka V. Subviral herpes simplex vaccine. In: Bonneau M, Hennessen H (eds): Develop Biol Standard Vol 52. Karger, Basel, 1982:313-319.
25. Sanchez-Pescador L, Burke RL, Ott G et al. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol 1988;141:1720-1727.
26. Burke RL, Goldbeck C, Ng P et al. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 1994;170:1110-1119.
27. Langenberg AGM, Burke RL, Adair SF et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and efficacy. Ann Intern Med 1995;122:889-898.
28. Leroux-Roels G, Moreau E, Desombere I et al. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2) candidate vaccine with MPL. In: Abstracts 34th Interscience Conf on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994:205 (abstract H57).
29. Heineman TC, Connelly BL, Bourne N et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1996;69:8109-8113.
30. Ulmer IB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
31. Tang D-C, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-154.
32. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci (USA) 1993;90:11478-11482.
33. Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996;173:800-807.
34. Schiff BL, Kern AB. Multiple smallpox vaccinations in the treatment of recurrent herpes simplex. Postgrad Med 1954;15:32-36.
35. Lazar MP. Vaccination for recurrent herpes simplex infection: initiation of a new disease site following the use of unmodified material containing live virus. Arch Dermatol 1956;73:70-71.
36. -) MRC5 given after an initial clinical episode in the prevention of herpes genitalis. Br J Vener Dis 1983;59:311-313.
37. Kutinova L, Benda R, Kalos Z et al. Placebo-controlled study with subunit herpes-simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine 1988;6:223-228.
38. Stanberry LR, Burke RL, Myers MG. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J Infect Dis 1988;156:156-163.
39. Myers MG, Bernstein DI, Harrison CJ et al. Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervico-vaginal virus shedding in guinea pigs. Antiviral Res 1988;10:83-88.
40. Stanberry LR, Harrison CJ, Bernstein DI et al. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res. 1989;11:203-214.
41. Ho RJY, Burke RL, Merigan TC. Antigen-presenting liposomes are effective in the treatment of recurrent herpes simplex virus genitalis in guinea pigs. J Virol 1989;63:2951-2958.
42. Straus SE, Corey L, Burke RL et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343:1460-1463.